ArticleThe Journal of antimicrobial chemotherapy2016
Identification and characterization of haemofungin, a novel antifungal compound that inhibits the final step of haem biosynthesis.
Article in The Journal of antimicrobial chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Mucormycosis during COVID-19 era: A retrospective assessment.Infectious medicine · 2024Review
- Review
- AlternativeFrontiers in cellular and infection microbiology · 2024Review
- Powerful and Real-Time Quantification of Antifungal Efficacy against Triazole-Resistant and -Susceptible Aspergillus fumigatus Infections in Galleria mellonella by Longitudinal Bioluminescence Imaging.Microbiology spectrum · 2023Article
- Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.Journal of clinical medicine · 2022Review
- Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- In Vivo Efficacy of Voriconazole in aJournal of fungi (Basel, Switzerland) · 2021Article
- Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi.Memorias do Instituto Oswaldo Cruz · 2021Article
- Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.Frontiers in microbiology · 2021Review
- Review
- Bioactive Peptides Against Fungal Biofilms.Frontiers in microbiology · 2019Review
- The Use ofJournal of fungi (Basel, Switzerland) · 2018Review
- Therapy of Mucormycosis.Journal of fungi (Basel, Switzerland) · 2018Review
- Methodologies forMicrobial cell (Graz, Austria) · 2018Review
- Additional oxidative stress reroutes the global response of Aspergillus fumigatus to iron depletion.BMC genomics · 2018Article
- Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.Frontiers in microbiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesDuring recent decades, the number of invasive fungal infections among immunosuppressed patients has increased significantly, whereas the number of effective systemic antifungal drugs remains low and unsatisfactory. The aim of this study was to characterize a novel antifungal compound, CW-8/haemofungin, which we previously identified in a screen for compounds affecting fungal cell wall integrity.
methodsThe in vitro characteristics of haemofungin were investigated by MIC evaluation against a panel of pathogenic and non-pathogenic fungi, bacteria and mammalian cells in culture. Haemofungin mode-of-action studies were performed by screening an Aspergillus nidulans overexpression genomic library for resistance-conferring plasmids and biochemical validation of the target. In vivo efficacy was tested in the Galleria mellonella and Drosophila melanogaster insect models of infection.
resultsWe demonstrate that haemofungin causes swelling and lysis of growing fungal cells. It inhibits the growth of pathogenic Aspergillus, Candida, Fusarium and Rhizopus isolates at micromolar concentrations, while only weakly affecting the growth of mammalian cell lines. Genetic and biochemical analyses in A. nidulans and Aspergillus fumigatus indicate that haemofungin primarily inhibits ferrochelatase (HemH), the last enzyme in the haem biosynthetic pathway. Haemofungin was non-toxic and significantly reduced mortality rates of G. mellonella and D. melanogaster infected with A. fumigatus and Rhizopus oryzae, respectively.
conclusionsFurther development and in vivo validation of haemofungin is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.